$437 Million is the total value of Fairmount Funds Management LLC's 27 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 31.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO | $38,497,000 | +35.7% | 264,206 | +10.4% | 8.81% | +31.3% |
| AXSM | AXSOME THERAPEUTICS INC | $36,100,000 | -7.5% | 942,571 | 0.0% | 8.26% | -10.4% | |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $35,370,000 | – | 3,343,107 | +100.0% | 8.10% | – |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $30,461,000 | -25.6% | 953,396 | -19.4% | 6.97% | -28.0% |
| ARGX | Sell | ARGENX SEsponsored adr | $27,858,000 | -28.9% | 73,526 | -40.8% | 6.38% | -31.2% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $27,587,000 | – | 283,000 | +100.0% | 6.31% | – |
| INSM | Sell | INSMED INC | $26,156,000 | -42.9% | 1,326,368 | -31.9% | 5.99% | -44.7% |
| COGT | Buy | COGENT BIOSCIENCES INC | $24,886,000 | +113.1% | 2,758,975 | +77.0% | 5.70% | +106.3% |
| Buy | NUVALENT INC | $23,262,000 | +25.1% | 1,715,518 | +28.2% | 5.32% | +21.1% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $22,182,000 | -33.6% | 469,264 | 0.0% | 5.08% | -35.7% | |
| BGNE | New | BEIGENE LTDsponsored adr | $18,030,000 | – | 111,400 | +100.0% | 4.13% | – |
| CTIC | New | CTI BIOPHARMA CORP | $13,408,000 | – | 2,245,891 | +100.0% | 3.07% | – |
| PNT | Sell | POINT BIOPHARMA GLOBAL INC | $12,489,000 | -32.2% | 1,833,950 | -20.7% | 2.86% | -34.4% |
| DBVT | New | DBV TECHNOLOGIES SAsponsored adr | $12,319,000 | – | 4,831,155 | +100.0% | 2.82% | – |
| VRDN | VIRIDIAN THERAPEUTICS INC | $10,923,000 | -37.4% | 944,092 | 0.0% | 2.50% | -39.4% | |
| ANNX | Buy | ANNEXON INC | $10,905,000 | +219.8% | 2,892,600 | +131.6% | 2.50% | +209.7% |
| OLMA | OLEMA PHARMACEUTICALS INC | $10,864,000 | -4.5% | 2,669,300 | 0.0% | 2.49% | -7.5% | |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $10,593,000 | -62.2% | 751,804 | -35.0% | 2.42% | -63.4% |
| Buy | TYRA BIOSCIENCES INC | $10,132,000 | -26.3% | 1,416,998 | +10.3% | 2.32% | -28.7% | |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $8,321,000 | -38.8% | 5,584,837 | +35.1% | 1.90% | -40.8% |
| KROS | Sell | KEROS THERAPEUTICS INC | $7,529,000 | -65.1% | 272,498 | -31.3% | 1.72% | -66.2% |
| TRVI | New | TREVI THERAPEUTICS INC | $4,565,000 | – | 1,624,389 | +100.0% | 1.04% | – |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $4,301,000 | -33.7% | 389,588 | 0.0% | 0.98% | -35.9% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $3,882,000 | -16.0% | 926,602 | 0.0% | 0.89% | -18.8% | |
| TIL | INSTIL BIO INC | $3,113,000 | -57.0% | 673,905 | 0.0% | 0.71% | -58.4% | |
| ASTRIA THERAPEUTICS INC | $2,735,000 | -55.3% | 911,736 | 0.0% | 0.63% | -56.7% | ||
| ALLK | ALLAKOS INC | $461,000 | -45.0% | 147,189 | 0.0% | 0.11% | -46.5% | |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -549,988 | -100.0% | -3.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.